Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?

Vista sencilla de ítem
dc.creatorMachiels, Julian D
dc.creatorBleeker-Rovers, Chantal P
dc.creatorHeine, Rob ter
dc.creatorRahamat-Langendoen, Janette
dc.creatorde Mast, Quirijn
dc.creatorOever, Jaap ten
dc.creatorBousema, Teun
dc.creatorvan Crevel, Reinout
dc.creatorWertheim, Heiman FL
dc.date.accessioned2020-07-24T19:25:41Z
dc.date.available2020-07-24T19:25:41Z
dc.date.created2020-06-12
dc.description.abstractenglishThe severity of COVID-19 has resulted in a global rush to find the right antiviral treatment to conquer the pandemic and to treat patients. This requires reliable studies to support treatment. In a recently published study by Gautret et al. the authors concluded that hydroxychloroquine monotherapy and hydroxychloroquine in combination with azithromycin reduced viral load. However, this trial has several major methodological issues, including the design, outcome measure and the statistical analyses. In this paper we discuss the background, clinical evidence, pharmacology and methodological issues related to this clinical trial. We understand the rush to release results, however in case conclusions are far reaching the evidence needs to be robust.spa
dc.format.extent4 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.ijantimicag.2020.106056spa
dc.identifier.issn0924-8579spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0924857920302260?via%3Dihub#abs0002spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11116
dc.publisherInternational Journal of Antimicrobial Agentseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subject(Hydroxy)chloroquinespa
dc.subject2019-nCoVspa
dc.subjectAzithromycinspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleReply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Reply-to-Gautret-et-al--hydroxychloroquine-sulfate-a_2020_International-Jour.pdf
Tamaño:
312.83 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS